We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -1.83% | 4.84 | 4.86 | 4.97 | 11,960 | 11:27:37 |
From May 2019 to May 2024
The Chairman's Award is presented to a member company or individual that best exemplifies excellence in Maryland's technology or life science industry. The Award recognizes a company that is a pillar in the community, not only through market success or job creation, but by consistently giving back, getting involved and advancing the climate for innovation.
“Novavax is the embodiment of what we look for when selecting an honoree for the Chairman’s award. The company has built a successful business, employing 450 people in Maryland who are developing vaccines that positively impact global health, and has played an important role in fostering growth of the state’s life sciences community,” said Rene B. LaVigne, TCM chairman-elect and president and CEO of Iron Bow Technologies. "TCM appreciates Novavax’s significant contributions to the association, the state’s economy and innovations in healthcare."
“I am honored to accept this award on behalf of the entire Novavax team,” said Stanley C. Erck, President and CEO, Novavax. “The Tech Council of Maryland facilitates a collaborative community of technology and life science companies who aim to make an impact in our region and beyond. We are thrilled that this award recognizes the hard work and dedication of our more than 450 SuperNovas, our groundbreaking achievements in developing novel vaccines and our commitment to the Maryland life science and technology community.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations ir@novavax.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com 212-845-4271
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
